According to Heemann et al. 13, elevations of circulating levels of TNFR and high circulating levels of soluble TNFR2 are negative predictors of treatment response in T-cell non-Hodgkin lymphomas. The gene discussed is TNFRSF1B; the disease is T-cell non-Hodgkin lymphoma.